Completed Access to Information Requests

Follow:

  • RSS
  • Cite
About this information

Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA). For additional information, please see the “About Access to Information Requests” webpage.

If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.

*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.

Download datasets of the summaries of completed access to information requests.

Report Type

Organization

Disposition

Year

Month

Found 60448 record(s)

Req # A-2022-000412

For the period beginning January 1, 2021 to June 28, 2022, all records and documentation related to any complaints received and/or investigations conducted by Health Canada; and correspondence between Health Canada and Canadian Food Inspection Agency (CFIA) in respect of the compliance of BioSteel brand products with regulatory obligations, including those pertaining to product labelling, advertising and formulations.

Organization: Health Canada

62 page(s)
January 2024

Req # A-2022-000449

Correpondence relating to any abbreviated new drug submission filed since March 1, 2022 where the dosage form is a desmopressin orally disintegrating tablet (melt tablet). Exclude module 3 and 5.

Organization: Health Canada

1014 page(s)
January 2024

Req # A-2022-000909

The most current status of the Abbreviated New Drug Submission (ANDS) seeking approval of a generic degarelix acetate product (Control No. 245431), which last received a Screening Acceptance Letter from Health Canada on March 7, 2022 for the sponsor’s Response to a Notice of Non-Compliance, dated August 23, 2021.

Organization: Health Canada

9 page(s)
January 2024

Req # A-2022-001171

All correspondence between Health Canada and British Colombia provincial organizations and/or officials on the matter of Delta-8-Tetrahydrocannabinol between June 1st 2022 and December 5, 2022.

Organization: Health Canada

171 page(s)
January 2024

Req # A-2022-001211

Number of memoranda of understanding on cooperation and information sharing with Indigenous communities signed in Quebec since the adoption of the Cannabis Act on October 17, 2018; document of the agreement with the Mohawk Council of Akwesasne; document of the agreement with the Mohawk Council of Kahnawà:ke; document of the agreement with Mohawk Council of Kanesatake. The number of inspections conducted by Health Canada in Indigenous communities in Quebec.

Organization: Health Canada

16 page(s)
January 2024

Req # A-2023-000013

The initial cover letter indicating the brand name of the reference drug product and the dosage form of the generic drug in Health Canada’s list of “Generic Drug Submissions Under Review” dated 2023-03-24 for the medicinal ingredient Tacrolimus. The Screening Acceptance Letter from Health Canada to the generic drug manufacturer confirming completion of screening of the Abbreviated New Drug Submission (ANDS) for Tacrolimus which appears in Health Canada’s list of “Generic Drug Submissions Under Review” dated 2023-03-24. The strength (s) and dosage form of any and all generic drugs in Health Canada’s list of “Generic Drug Submissions Under Review” dated 2023-03-24 for the medicinal ingredient Tacrolimus.

Organization: Health Canada

4 page(s)
January 2024

Req # A-2023-000483

A list of every drug approved under Health Canada's Special Access Program (SAP) between January 1, 2018 and July 6, 2023.

Organization: Health Canada

5266 page(s)
January 2024

Req # A-2023-000552

Correspondence relating to any abbreviated new drug submission (ANDS) filed after January 1, 2023 for Estradiol tablets by vaginal route of administration.

Organization: Health Canada

14 page(s)
January 2024

Req # A-2023-000594

All notes made by the Health Canada employees who reviewed the AstraZeneca Vaxzevria COVID-19 vaccine, in relation to the review, that were made during the reviewal process of the drug. Date Range: January 1, 2020 to July 31, 2020.

Organization: Health Canada

0 page(s)
January 2024

Req # A-2023-000601

All notes made by the Health Canada employees who reviewed the Janssen Jcovden (Johnson & Johnson) COVID-19 vaccine, in relation to the review, that were made during the reviewal process of the drug. Date Range: January 1, 2020 to July 31, 2020.

Organization: Health Canada

0 page(s)
January 2024

What's new in open government?

Date modified: